SiO2 Medical Products Primary Containers – Reduces Risk of Adverse Biologic Drug Reactions

Download This Report

Please complete the form below and we will email the report.



    SiO2 Medical Products Primary Containers – Reduces Risk of Adverse Biologic Drug Reactions

    By Christopher Weikart, PhD, Chief Scientist, SIO2 Materials Science

    The primary container (e20191009_Biotech Drug Stability and Immunogenicity_Final-2x. vial or syringe) needs to maintain the efficacy (prevent degradation) of the drug throughout the shelf life. Biologic drugs are far more prone to degradation compared to traditional small molecule drugs. When a biologic drug experiences degradation and injected into a patient, the body’s immune system can be triggered. This may result in severe adverse drug reactions that may require that the patient…